This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
by Zacks Equity Research
Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.
Is it the Right Time to Retain Abbott Stock in Your Portfolio?
by Zacks Equity Research
ABT's strong Nutrition, Diabetes Care and EPD growth fuel momentum, but macro and currency headwinds challenge its outlook.
Baxter Stock Slips Despite Latest Launch to Boost Patient Monitoring
by Zacks Equity Research
BAX launches FDA-cleared Connex 360 monitor, aiming to boost frontline care and streamline patient monitoring.
Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up
by Zacks Equity Research
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
Here's Why Masimo (MASI) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LH Stock Rises on Acquisition of BioReference Health's Select Assets
by Zacks Equity Research
Labcorp's $225M acquisition of BioReference Health select assets boosts its oncology diagnostics portfolio and expands patient access nationwide.
The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock
by Zacks Equity Research
Thermo Fisher unveils the Olink Target 48 Neurodegeneration panel to accelerate biomarker research in neurodegenerative diseases.
Should You Continue to Hold Integra Stock in Your Portfolio Now?
by Zacks Equity Research
IART shows strong demand in neurosurgery and Tissue Technologies but faces macro and liquidity challenges.
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
by Zacks Equity Research
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio
by Zacks Equity Research
QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
by Zacks Equity Research
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Should You Add IDEXX Stock to Your Portfolio Right Now?
by Zacks Equity Research
IDXX shows strong CAG Diagnostics growth, cloud software momentum and global expansion but faces solvency and macro risks.
CRL Stock Rises Following New Strategic Oncology Collaborations
by Zacks Equity Research
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
by Zacks Equity Research
Envista's global expansion, strategic acquisitions, and solid solvency boost growth outlook despite FX headwinds.
Should You Continue to Hold EXAS Stock in Your Portfolio?
by Zacks Equity Research
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Here's Why You Should Add PAHC Stock to Your Portfolio Right Now
by Zacks Equity Research
Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.
ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay
by Zacks Equity Research
The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.
Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?
by Zacks Equity Research
GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
by Zacks Equity Research
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
New Strong Buy Stocks for September 4th
by Zacks Equity Research
LRN, RL, ATRO, MASI and BYD have been added to the Zacks Rank #1 (Strong Buy) List on September 4, 2025.
QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise
by Zacks Equity Research
QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
by Zacks Equity Research
RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.
Charles River Stock May Benefit From Joining EASYGEN Consortium
by Zacks Equity Research
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
by Zacks Equity Research
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Post Holdings, Service Corporation International, TAL Education Group, Masimo and Okta.